Diabetes Drug Could Help Prevent Blood Clot Formation
New research suggests a common diabetes medication may reduce clotting risks by inhibiting specific platelet proteins.
Updated on Oct. 28, 2026 in Diabetes
Live Poll
Should medical research prioritize discovering cardiovascular benefits in existing FDA-approved medications?
Michigan Medicine researchers have identified a biological mechanism that explains how the medication sotagliflozin reduces blood clot formation. This preliminary study in mice and human blood samples may help clarify why this specific drug differs in cardiovascular outcomes compared to other inhibitors.
Why it matters
Understanding how different diabetes medications impact blood clotting is crucial for preventing heart attacks and strokes. This research helps explain the potential cardiovascular benefits of sotagliflozin beyond standard glucose control.
In a preclinical study, researchers found that sotagliflozin reduced clot formation in mice by 60% compared to 5-10% with empagliflozin. While these results show significant promise, the findings remain preliminary and require further investigation in human trials.
The players
Michigan Medicine
An academic medical center that leads clinical research and patient care initiatives.
University of Michigan Medical School
A research institution focused on advancing medical science through rigorous study.
The details
Sotagliflozin works by inhibiting both SGLT1 and SGLT2 proteins in the body. By blocking SGLT1 on platelets, the drug prevents them from becoming overly activated, which is a primary step in the formation of blood clots. This dual-inhibition mechanism differentiates it from other SGLT2 inhibitors that primarily target the kidneys.
Timeline
October 28, 2026: Study results published in the Journal of Clinical Investigation.
Health Landscape
This development adds to the evolving research surrounding SGLT1 and SGLT2 inhibitor therapies for metabolic health. It helps distinguish how dual-acting medications potentially impact cardiovascular risk factors differently than previous standards of care.
These findings are early-stage and do not change current treatment recommendations for managing diabetes. If you are taking medication for blood sugar or heart health, discuss your current regimen and any new research with your physician before considering changes.
The takeaway
This study highlights that not all diabetes medications act on the body in the same way regarding cardiovascular health. Monitor your heart health through regular checkups and keep an open dialogue with your doctor about how your medications impact your overall well-being.
What happens next
Researchers intend to evaluate the drug's effects on patients with chronic kidney disease and atrial fibrillation.
Further reading
For more on managing metabolic health, visit our Diabetes section.
More information
Review the full Journal of Clinical Investigation research article to learn more about the study design.
Live Poll
Should medical research prioritize discovering cardiovascular benefits in existing FDA-approved medications?
